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http://dx.doi.org/10.1016/j.hkpj.2013.03.00Abstract In this narrative review of the literature, we discuss the influence of chemotherapy
treatment on peak aerobic power (VO2peak) for women with breast cancer and the mechanisms
for exercise intolerance. In specific, we examine the central, peripheral, and oxygen transport
mechanisms responsible for exercise intolerance in women living with breast cancer. Our find-
ings indicate that reduced ventricular contractility, reduced left ventricular (LV) compliance,
and increased afterload are (in part) responsible for exercise intolerance secondary to chemo-
therapy treatment. It appears that changes in central haemodynamics and morphology often
occur preceding clinical diagnosis of cardiotoxicity (LV ejection fraction <55%), which explain
the attenuated exercise tolerance for this population. Patients with breast cancer are unable
to make use of the FrankeStarling mechanism to increase stroke volume in response to an in-
crease in end-diastolic volume. They may be able to increase preload during exercise condi-
tions; however, reduced LV filling mechanics (in part due to an increase in pericardial
restraint) and decreased contractile reserve may ultimately contribute to a reduced exercise
tolerance for women with breast cancer. Recent evidence indicates that peripheral maladap-
tations and alterations in haemoglobin concentration are additional mechanisms that may limit
VO2peak and exercise tolerance in patients with breast cancer.
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2Introduction
Breast cancer is the leading cause of death and the most
common form of cancer amongst women worldwide. In
2008, the International Agency for Research on Cancer
estimated that there were approximately 1.38 million
women diagnosed with breast cancer worldwide accountingsociation Ltd. Published by Elsevier (Singapore) Pte Ltd. All rights reserved.
3for approximately 23% of all diagnoses of cancer [1]. With
advancement in treatment methodologies and improve-
ments in early detection, approximately 89% of women
survive up to 5 years following treatment cessation [2].
With improvements in survivorship (i.e., the period from
diagnosis to the end of life), more individuals are at higher
risk of age-related co-morbidities (most survivors are over
the age of 65), disease sequelae, and cytotoxic ailments
associated with treatment [3].
Treatment for early-stage breast cancer is focused on
cure and prevention of relapse of disease and usually
consists of chemotherapy, radiation, endocrine, human
epidermal growth factor receptor 2 (HER2)-targeted ther-
apies or a combination of these treatments. Emerging evi-
dence suggests that molecular targets of cancer therapies
are not tissue specific and may result in significant
myocardial tissue and vascular injury. Traditionally,
chemotherapy-induced cardiotoxicity is associated with
left ventricular (LV) dysfunction leading to progressive
heart failure (HF) with changes in diastolic and systolic
function. Cardiotoxicity is often defined as a reduction in LV
ejection fraction (LVEF) of at least 5% from baseline to less
than 55% with signs or symptoms of congestive HF, or an
asymptomatic decline in LVEF of at least 10% from baseline
to below 55% [4]. Across the cancer trajectory, there is a
profound reduction in exercise tolerance (particularly
during chemotherapy) [5]. However, resting LVEF and other
resting indices of LV function have been shown to correlate
poorly with exercise tolerance and not all women present
with impaired LVEF during and following treatment [6,7]. It
has been argued that the lack of relationship between
resting indices of cardiac function and exercise tolerance
suggests that other myocardial morphological changes or
peripheral factors are major determinants of exercise
tolerance in women with breast cancer. However, resting
indices of cardiac function are also poor predictors of ex-
ercise cardiac function. As such, exercise measures of
cardiac function are evaluated to more clearly determine
the relationship with exercise intolerance in breast cancer
(similar to other chronic conditions) [8].
Peak aerobic power (VO2peak) is the gold standard for
assessing cardiovascular fitness and is a significant inde-
pendent predictor of overall health and survival in in-
dividuals with cancer [9,10]. In specific, VO2peak has been
shown to predict chemotherapy-induced LV dysfunction and
predict cardiovascular disease (CVD) risk factors (e.g.,
blood pressure, lipid profile, C-reactive protein) for in-
dividuals with cancer [11,12]. The VO2peak for individuals
with a history of breast cancer is consistently 30% below
that of age- and gender-matched inactive individuals
without a history of breast cancer [13]. This research is
compelling, because VO2peak is an indication of overall well
being and a minimal threshold of VO2peak has been estab-
lished for functional independence (i.e., 15.4 mL/kg/min
for women) [9]. Many individuals with breast cancer are at
an increased risk of functional dependence and reduced
health status. Therefore, it is important to consider those
factors that limit VO2peak in patients with breast cancer in
order to gain a complete understanding of the disease and
its available treatment options. According to the Fick
equation, limitations in VO2peak contribute to a reduction in
cardiac output (Q) or arteriovenous oxygen difference andtheir respective determinants. The arteriovenous oxygen
difference is often considered classically as a peripheral
determinant of oxygen consumption. However, the central
determinants of oxygen consumption are generally related
to oxygen transport, which is a product of the oxygen-
carrying capacity of blood and Q. More recent studies
have also examined the molecular mechanisms by which
central oxygen delivery and peripheral oxygen utilization
may be affected by chemotherapy. Accordingly, in this
current narrative review, we examine the underlying cen-
tral, peripheral, and molecular mechanisms that contribute
to a reduction in VO2peak values and exercise intolerance in
women with breast cancer.
Cytotoxic treatments
Some of the most active agents used in traditional chemo-
therapy treatment are anthracyclines, such as doxorubicin
and epirubicin [14]. Trastuzumab (Herceptin), a recombi-
nant DNA-derived humanizedmonoclonal antibody targeting
the proto-oncogene in HER2/neu cancer cells, is a newly
recognized drug used in the treatment of early-stage breast
cancer. Bevacizumab, the newest cytotoxic agent, and
other tyrosine kinase inhibitors attenuate tumour growth by
inhibiting angiogenesis. Despite their clinical efficiency,
these drugs have been associated with cardiac and vascular
injury leading to adverse cardiac events [15e19].
Anthracyclines
Anthracyclines are active agents used for the treatment of
breast cancer; however, their clinical use is limited due to
the toxicity profile of the myocardial tissue. The molecular
mechanisms responsible for the antitumour effects of
anthracycline treatment are different from those respon-
sible for their cardiotoxic effects. They diffuse across the
cellular membrane and are responsible for DNA and RNA
interactions, resulting in inhibition of DNA and RNA syn-
thesis, which ultimately induces cell death [20,21].
Anthracycline-mediated cell death of tumour cells is linked
to the activation of apoptosis signal-transduction pathways
through intrinsic and extrinsic activation of caspases, a
common death effector molecule [22]. The tumour necrosis
factor-a and CD45 are key signal pathways that are
responsible for recruitment of adaptor molecules, such as
Fas-associated protein with death domain that is respon-
sible for caspase activation, subsequently inducing cell
death. Conventionally, anthracyclines also converge on the
mitochondria, thereby increasing permeabilization and in-
duction of intrinsic apoptotic pathways. This leads to a
mitochondrial release of cytochrome c, increased activa-
tion of tumour suppressor p53, and pro-apoptotic Bcl-2
family of proteins BAD and BAX [23]. Sequentially, there is
an influx in cellular reactive oxygen species (ROS) and
alcohol metabolites [24], which exacerbates mitochondrial
DNA damage, subsequently impairing the function of the
electron-transport chain, reducing adenosine triphosphate
(ATP) synthesis, and altering calcium and iron homeostasis
in myocardial tissues [25]. Specifically, oxidative stress
initiates mitochondrial permeability leading to alterations
in mitochondrial calcium transport. As a result, tissue injury
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an irreversible reduction in mitochondrial calcium-loading
capacity [26].
Anthracycline-induced cardiotoxicity, is in part contrib-
uted to an increase in ROS production, ultimately altering
myocardial function and integrity [27]. Oxidative stress
leads to damage of the cardiomyocytes, altering their
structure and arrangement in series resulting in myocardial
remodelling [28]. This can result in LV eccentric remodel-
ling, decreased LV wall thickness, and impaired LV
compliance. Moreover, anthracycline therapy contributes
to altered homeostasis of energy reserves of the myocar-
dium including decreased ATP and phosphocreatine levels
in mammalian cardiac tissues [29]. In the same way,
adenosine monophosphate-activated protein kinase levels
are reduced, inhibiting ATP production and decreasing
phosphorylation of acetyl-CoA carboxylase, a downstream
mediator of oxidative metabolism. As such, systolic and
diastolic function may be compromised due to suppressed
ATP production, which cannot sustain adequate contraction
and relaxation [28].
Because of these changes in myocardial performance,
systolic and diastolic function may be impaired for in-
dividuals with breast cancer. Mercuro et al [30] demon-
strated that administration of low doses of epirubicin,
cumulative dose of 300 mg/m2, was associated with a sig-
nificant impairment in diastolic function despite changes in
resting LVEF. These patients present with impaired ven-
tricular filling mediated by a reduction in ventricular
compliance and inappropriate relaxation, despite a pre-
served ejection fraction secondary to chemotherapy
treatment. Systolic impairment is also evident in a long-
term follow-up of childhood cancer survivors treated with
anthracyclines who underwent echocardiographic mea-
sures. Results of this investigation demonstrate that latent
effects of anthracyclines are associated with HF and sys-
tolic dysfunction. Of those treated with anthracyclines, 41%
presented with cardiac abnormalities and 31% of the pa-
tients had an increase in end-systolic wall stress. Abnor-
malities in the LV systolic function were also evident using
rate-corrected mean velocity of circumferential fibre
shortening and fractional shortening measurements with
impaired LVEF [31]. Taken together, these results demon-
strate that both systolic and diastolic dysfunctions are
associated with anthracycline treatment. Although these
clinical outcomes are important, even without an evident
reduction in LVEF due to breast cancer therapies, these
treatments may impose considerable long-term risk of HF
following early-stage breast cancer treatment.Trastuzumab
Trastuzumab is a humanized monoclonal antibody directed
against the extracellular domain of the tyrosine kinase re-
ceptor (HER2) and has been shown to exert a variety of
antitumour effects for breast cancer cells with HER2 over-
expression. Overexpression of this receptor occurs in
20e30% of women with early breast cancer and is associ-
ated with poor prognosis and resistance to chemotherapy
[32e34]. Receptor-specific ligand binding of the HER2 re-
ceptor induces both cell proliferation and survival throughphosphorylation of intracellular tyrosine kinase domains.
Phosphorylation of the intracellular kinase domains acti-
vates the lipid kinase phosphoinositide 3-kinase (PI3K)/Ak-
transforming factor (AKT) pathway driving cell survival, cell
growth, and cell cycle entry through phosphorylation of
other host proteins [35]. The PI3K/AKT pathway signalling
promotes cell survival by inhibiting the activity of pro-
apoptotic B-cell lymphoma 2 (Bcl-2) family members (BAD
and BAX) [36]. The AKT pathway also hinders negative
regulation of the transcription factor nuclear factor-kB and
forkhead transcription factors, thereby leading to
increased transcription of antiapoptotic and prosurvival
genes and a reduction in the production of cell death-
promoting proteins, respectively [37]. In parallel, ligand
binding of the HER2 receptor phosphorylates the SH2
domain of guanosine triphosphatase-activating protein,
which leads to the activation of the mitogen-activated
protein kinase/extracellular signal-regulated kinases
pathway, thereby driving cell proliferation and survival.
Downstream targets of this pathway also support the acti-
vation of vascular endothelial growth factor (VEGF) sup-
porting angiogenesis and tumor growth. Mutational
activation of the PI3K/AKT pathway including gene ampli-
fication and activation of key components of the PI3K/AKT
pathway such as PIK3CA and AKT1, or loss of tumour sup-
pressor gene phosphatase and tensin homologue are com-
mon in breast malignant tumours [38]. Trastuzumab inhibits
these signalling cascades by inhibiting cell growth and
proliferation.
Despite the clinical efficacy of trastuzumab for its
antitumourigenic effects, clinical studies have proposed
that the expression of HER2 and associated ligands is
essential for cardiac structure, function, and cardiac
response to stress. In specific, cardiac expression of HER2
receptors protect the heart from structural changes,
whereas disruption in HER2 expression leads to decreases in
LV function and cardiomyopathy [39]. Basic science
research demonstrates that conditional mutations of
ErBb2/HER2 lead to both LV dilation and hypertrophic
changes, and subsequently a marked reduction in LV
contractility in adulthood. These changes were accompa-
nied with a decrease in survival when subjected to pressure
overload with aortic banding [40]. Interestingly, no changes
in the rates of apoptosis or myofibril structure were
observed in this investigation. Further, trastuzumab treat-
ment is suggested to impair cardiomyocyte differentiation
and reduce ATP synthesis in human cardiac stem cells [41].
Indeed, administration of trastuzumab is associated with
functional changes in cardiomyocytes; however, changes in
the structural integrity of the cardiomyocytes are not
certain. Neuregulin 1 (Nrg1), an agonist for the activation
of ErBb2 signalling, and downstream targets ERK and Akt
pathways are important for cardiac development [42].
Trastuzumab blocks this activation and leads to alterations
in the levels of the Bcl-X family members, mitochondrial
dysfunction, energy compromise, and cytochrome c release
[43]. Further, a two-hit model of trastuzumab-induced
cardiotoxicity has been suggested in which administration
of trastuzumab results in a loss of HER2-mediated signalling
and interferes with the heart’s ability to respond to stress
[44]. When administered with anthracyclines, the increased
mitochondrial damage and increased ROS production
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deficient hearts are more susceptible to the risk of irre-
versible cardiotoxicity. However, following treatment
cessation, cardiotoxicity in some cases is reversible,
whereas for others it may result in long-term irreversible
cardiac damage. These clinical consequences increase the
patient’s risk of CVD, an outcome that is increasingly
recognized as an important co-morbidity associated with
HER2-directed therapies.
Significant cardiac safety concerns from anticancer
therapy have been described with trastuzumab treatment.
The mechanisms underlying the early impairment of dia-
stolic function with respect to systolic function are not well
established. An analysis of the data reported by Sawaya
et al [45] found that administration of trastuzumab was
associated with abnormalities in LV function with an 11%
reduction in longitudinal strain rate, a measure of systolic
LV function, and an early indicator of cardiac dysfunction of
the midwall, anterior, and lateral segments preceding a
decrease in LVEF. Chemotherapy-induced cardiac injury
may result in microvascular abnormalities through VEGF
inhibition and lead to interstitial fibrosis. The LV longitu-
dinal strain depends on the subendocardial layers of the
myocardium and influences diastolic function [46], sug-
gesting that diastolic function may be impaired before
clinical changes in systolic function, which are indicated by
a reduction in strain rate. Echocardiographic measures
suggest that trastuzumab treatment may be associated
with systolic dysfunction, which may be accompanied by
reduced diastolic LV function preceding a decrease in LVEF
for women with breast cancer.Angiogenesis inhibition
Some of the newest agents used in the treatment of breast
cancer are receptor tyrosine kinase inhibitors such as bev-
acizumab designed to target the VEGF family of peptide
growth factors and its cognate receptor VEGF2, which are
central regulators of angiogenesis and metastatic propa-
gation [47]. The VEGF expression has been reported in over
60% of breast cancer specimens and correlates with shorter
survival time following diagnosis [48], suggesting the
effectiveness of anti-VEGF therapy in the oncology setting.
Angiogenesis-targeting therapies result in decreased endo-
thelial cell proliferation and an increase in apoptosis with
the release of cytochrome c to the cytosol-activating cas-
pase 9, which initiates the mitochondrial apoptotic path-
ways [49]. The effect of VEGF signalling on cardiovascular
function highlights that signalling systems are not tissue
specific. Hypertension is often associated with VEGF-target
therapies due to its role in regulating the release of potent
vasodilators, nitric oxide, and prostaglandins [50]. When
the heart is placed under hypertensive stress resulting in
hypoxia or ischaemia, VEGF and endothelium-specific mi-
togens stimulate angiogenesis [18]. The VEGF activation of
VEGF receptor on endothelial cells initiates vasodilation
and angiogenesis in the heart and allows for compensatory
cardiac hypertrophy to occur. Impedance of this cascade of
events with chemotherapeutic treatments results in an in-
crease in blood pressure [51] and may hinder the ability of
the myocardium to compensate for an increase in afterloadon the heart. Hypertension due to VEGF inhibition places an
increase in afterload on the heart, and may lead to similar
morphological changes of the myocardium as HF associated
with diastolic dysfunction. Belcik et al [52] demonstrated
that mice treated with VEGF receptor tyrosine kinase in-
hibitors exhibited concentric LV remodelling and reduced
stroke volume (SV) in the absence of impaired LV contrac-
tility determined by LV peak change in pressure over time
(dp/dt).
Exercise tolerance in breast cancer
Peak aerobic capacity is an individual’s capacity to trans-
port oxygen from the atmosphere to the mitochondria of
the muscle for ATP resynthesis requiring the integrative
capacity of the respiratory, circulatory, and musculoskel-
etal systems [53]. Impedance along the oxygen cascade as a
result of injury, toxicity, or dysfunction of the respiratory,
circulatory, musculoskeletal systems will lead to a decrease
in VO2peak and a consequential decrease in exercise toler-
ance. Conventional breast cancer therapies may impede
the function and integrity of the cascade involved in oxygen
transport leading to the development of important cardio-
vascular consequences. The reduced exercise tolerance for
patients with breast cancer may also contribute to indirect
lifestyle perturbations (e.g., physical inactivity, weight
gain) preceding cancer therapy or as a direct consequence
of cancer and its treatment.
Central haemodynamics
There is substantial evidence related to the relative change
in central haemodynamics in women with breast cancer
both during and following cytotoxic therapies. Considering
this, central haemodynamics may play an important role in
governing exercise intolerance in women with breast can-
cer. Jones et al [54] demonstrated that postmenopausal
women with breast cancer during survivorship had a 19%
reduction in VO2peak compared with age-matched healthy
controls. A reduction in VO2peak was associated with a
reduction in the SV and Q response with no significant dif-
ferences in arteriovenous oxygen difference during
maximal exercise conditions. Systemic vascular resistance
was also significantly increased during exercise conditions
for survivors of breast cancer suggesting a limitation to
forward flow from the aorta during ejection of the LV.
These findings suggest that the SV and Q response to ex-
ercise may be reduced in breast cancer patients with
reduced ability to increase VO2peak to the same end as their
healthy counterparts and that central haemodynamics may
play a very important role in exercise intolerance for
women with breast cancer.
Improvements in VO2peak have been achieved with aer-
obic exercise training for women with breast cancer
without a change in LVEF [55] when adherence predicted a
change in VO2peak. This is not surprising, because resting
LVEF does not necessarily correlate with improvements in
VO2peak, as shown previously in patients with chronic HF [6].
Because of this, other central haemodynamic measures
(and peripheral adaptations) are considered to determine
their role owing to the change in VO2peak for this
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reserve is of important interest. The Q response during in-
cremental aerobic exercise is dependent on heart rate and
SV. Factors that influence each of these variables will have
considerable influence on the Q response to exercise. Pre-
vious work from our laboratory has highlighted that the Q
response during incremental aerobic exercise is dependent
on heart rate, end-diastolic volume (EDV), ejection frac-
tion, and mitral regurgitant fraction and factors influencing
these variables will have a considerable influence on
VO2peak and exercise tolerance [8]. Given this, herein we
highlight the importance of these factors in the reduced
exercise tolerance of women with breast cancer.Reduced Q reserve with exercise: impaired cardiac
function
Early-stage breast cancer therapies may result in myocar-
dial injury causing functional and structural changes to the
myocardium, ultimately limiting the Q and SV response
during exercising conditions for women with breast cancer.
Many women with breast cancer present with a reduction in
LVEF and a significant reduction in strain rate in the longi-
tudinal, radial, and circumferential regions of the
myocardium [56] and markers of reduced LV systolic func-
tion at rest. Chronic HF patients with LV systolic dysfunc-
tion appear to use the FrankeStarling mechanism as a
compensatory mechanism to maintain SV with eccentric
remodelling. During exercise conditions, patients with a
history of breast cancer are able to increase EDV; however,
reduced contractile reserve may hinder the SV response to
meet the metabolic demands of the peripheral tissue.
Haykowsky et al [55] demonstrate that patients with an
evidence of LV dilation secondary to trastuzumab treat-
ment are unable to increase VO2peak during chemotherapy
treatment when systolic function was compromised. These
findings provide evidence that during exercise conditions,
patients with breast cancer are able to increase EDV (pre-
load); however, the Q reserve was limited with a marked
increase in end-systolic volume (ESV). Although EDV in-
creases during exercise conditions to maintain SV, the Q
response to exercise is limited by reduced function and
contraction of the LV resulting in an increase in ESV.
In the current oncology setting, an assessment of cardiac
function primarily relies on change in resting LVEF using
echocardiographic measures. However, resting LVEF may
not be a sensitive measure of early myocardial injury and
evidence suggests that diastolic cardiac performance may
prevent any change in asymptomatic LVEF. Moreover,
resting LVEF is a poor measure of exercise cardiac function.
Data from the study of Stoodley et al [57] assessed 53
women 1 week before and 1 week after the administration
of anthracyclines using tissue Doppler imaging to determine
changes in cardiac performance following chemotherapy.
These data indicated that anthracyclines impaired diastolic
function with reduced LV relaxation mechanics in the entire
cohort of women with no change in LVEF. Patients with LV
diastolic dysfunction have normal contractile function;
however, they are unable to make use of the FrankeStarl-
ing mechanism during exercise conditions. Diastolic
dysfunction (as demonstrated by an inability to increaseEDV during exercise) may be a latent effect of cytotoxic
treatment in breast cancer survivors. As a result, end-
diastolic pressure increases augmenting early LV filling.
Anthracycline-induced cardiotoxicity leads to impaired
diastolic filling and increased diastolic pressures at rest
[58]. However, it is not known whether exercise intolerance
is mediated by reduced diastolic function and ventricular
compliance resulting in increased diastolic filling pressures
during exercise conditions. Pulmonary capillary wedge
pressure and right atrial pressure are direct indicators of
diastolic function and clinical measures of inputs to the
heart. Right atrial pressure will determine blood flow back
to the heart (and therefore, EDV) and it is important to
maintain right ventricular filling to sustain global Q during
periods of exercise. To our knowledge, no studies to date
have used these direct measures of diastolic function dur-
ing exercise conditions to determine its influence on exer-
cise intolerance for women with breast cancer.
At present, diastolic ventricular function and its role in
exercise tolerance during incremental or maximal exercise
is not well studied for women with breast cancer. As
described previously, EDV may increase during exercise for
women with breast cancer. However, an acute increase in
intracardiac volume that occurs during moderate to heavy
aerobic exercise may result in a concurrent augmentation
in pericardial pressure that elevates the external constraint
to LV filling [59]. It may be plausible that a rise in EDV
during acute incremental exercise may be associated with
pericardial restraint leading to modulation of LV compli-
ance and filling for women with breast cancer. An acute
increase in intraventricular volume resulting in pericardial
restraint may induce changes in compliance that influence
both passive and active LV filling [60] during exercise con-
ditions. Further, pathological changes following breast
cancer treatment may also lead to an acute myopericarditis
and focal endocardial fibrosis with thickened and tense
pericardium, limiting ventricular compliance under exer-
cise conditions [61]. Overall, patients with breast cancer
may be able to increase preload during exercise conditions;
however, reduced LV-filling mechanics (in part, due to an
increase in pericardial restraint) and decreased contractile
reserve may ultimately lead to changes in central haemo-
dynamics that contribute to a reduced exercise tolerance
for women with breast cancer.Negative inotropic influence
Sympathetic innervation of the myocardium is autonomi-
cally controlled by the central nervous system and is
responsible for heart rate control. A change in ventricle
inotropy controlled by sympathetic innervation of the heart
may be responsible for changes in EDV and ESV and sequen-
tial changes in VO2peak. Chemotherapy treatment is associ-
ated with neuropathic injury making it possible that
sympathetic innervation of the myocardium may be
impaired. Tjeerdsma et al [62] investigated asymptomatic
(LVEF >50%) women with metastatic breast cancer for
autonomic regulation with a 24-hour Holter monitor using
time domain frequencies of the ReR interval following
anthracycline treatment. This investigation revealed
impaired autonomic control of heart rate in 85% of patients,
7particularly time-domain parameters related to lower
parasympathetic activity. Further, a reduction in para-
sympathetic activity may also result in ventricular tachy-
cardia noted in this investigation, leading to adverse
cardiovascular events and reduced Q reserve. Autonomic
incompetence plays an important role in the increase of Q
during exercise, and therefore, has a large influence on
VO2peak. The findings of this investigation are concurrent
with the results of other studies, in which vagal-mediated
fluctuations in heart rate variability were reduced, and
markers of sympathetic activity were unchanged [63]. Of
concern, autonomic control and diastolic function predicted
outcomes of dyspnea with exertion, hindering activities of
daily living for these individuals. Despite these findings, the
function of autonomic impairment following cytotoxic
treatment remains controversial. Feola et al [64] found
nonsignificant changes in heart rate following anthracyclines
treatment in the entire cohort of 53 breast cancer patients
with a statistically significant change in LVEF at 1-month
follow-up. These data suggest that during resting condi-
tions, sympathetic control of heart rate may be impaired,
which may influence heart rate during exercise conditions.
As seen in children with multiple malignancies, heart rate
was significantly lower during maximal exercise conditions
following anthracycline treatment when compared with
healthy individuals [65]. The consequence of impaired
sympathetic activity on heart rate control during maximal
exercise conditions and its influence on Q reserve for women
with breast cancer requires further investigation.Impaired vascular function
The effects of breast cancer treatments on vascular func-
tion and possible injury are not well studied. However,
numerous reports have demonstrated that treatments for
breast cancer are associated with an increased risk of hy-
pertension and impaired endothelial function.
Anthracycline-induced oxidative stress and impaired VEGF
receptor signalling will likely have detrimental effects on
the vascular system. This may lead to induction of the
atherosclerotic cascade associated with adhesion molecule
proliferation, nitric oxide uncoupling, increased pro-
inflammatory cytokines, and impaired endothelial vasodi-
lation [66,67]. These detrimental outcomes have been
demonstrated in clinical trials. Arterial pressure during
systole (and therefore, afterload) is largely dependent on
the function and structure of large elastic and muscular
arteries, which can be determined by the stiffness of the
aortic vessel [68]. Aortic stiffness, which is determined by
measuring central pulse wave velocity and aortic distensi-
bility, has been shown to be impaired following cytotoxic
treatments [69]. Thus, afterload on the heart, or the aortic
pressure the LV must overcome to eject blood into systemic
circulation may be increased following cytotoxic treatment
resulting in an increase in aortic stiffness. It is plausible
that during submaximal exercise conditions aortic stiffness
plays a key role in the limitation of LV mechanics, whereas
at higher workloads other factors including cardiac reserve
or pericardial restraint may be more important.
Clinical studies have shown that rapid depletion of sys-
temic nitrogen oxide bioavailability occurs following asingle dose of anthracyclines, resulting in endothelial
dysfunction measured noninvasively by flow-mediated
dilation [70]. Resultant outcomes of the change in endo-
thelial function may lead to acceleration of atherosclerosis
and hypertension following chemotherapy treatment for
women with breast cancer. Direct inhibition of VEGF re-
ceptors with angiogenesis inhibitors or indirect inhibition
with HER2 therapy is also limited in clinical use due to
marked increases in hypertension during and following
treatment. Mayer et al [71] demonstrated significant
changes in haemodynamic profiles for women with breast
cancer with an increase in systolic blood pressure, diastolic
blood pressure, and mean arterial pressure within 6 weeks
of vandetanib and metronomic chemotherapy treatment.
These participants were also assessed for nitrogen oxide
bioavailability and forearm vascular resistance. Forearm
vascular resistance was increased and nitrogen oxide
bioavailability was reduced. The ability to increase cardiac
output during exercise without an abnormal elevation in
left atrial pressure depends on the capacity of the LV to
enhance its diastolic filling [72]. However, elevated systolic
arterial blood pressure (a surrogate of afterload) impairs
diastolic performance. Thus, it is likely that elevated
afterload impairs Q reserve during exercise for women with
breast cancer.Muscle function
Early-stage breast cancer treatments may lead to overt
insult of the peripheral muscle tissue, whereas direct life-
style perturbations increase the risk for muscle atrophy and
impaired metabolic activity. Muscular atrophy is a serious
complication of chemotherapy treatment causing extreme
fatigue and weakness. Deterioration of skeletal muscle
results in symptomatic reduction in exercise tolerance and
altered peripheral muscle perfusion [73]. Improvements in
VO2peak are also associated with increased muscular
strength and size [74]. However, a reduction in muscle size
cannot fully explain their reduction in exercise tolerance.
Maladaptation of skeletal muscle or reduced oxidative
metabolism due to mitochondrial DNA damage may exist
within the skeletal muscle [75]. The consequence of
compromised peripheral blood perfusion, oxidative phos-
phorylation, and abnormal cellular structure of the skeletal
muscle may contribute to a reduced exercise tolerance for
women with breast cancer.
Bruera et al [76] examined the muscular function of pa-
tients with advanced breast cancer and compared the data
with healthy individuals, the results of which suggested that
persons with breast cancer have lower maximum strength
after supramaximal stimulation, a reduction in relaxation
velocity, and a higher loss of contractile strength, after 30
seconds of stimulation. These findings suggest that breast
cancer treatment may exert confounding alterations in
muscular function. Lifestyle factors including obesity or lack
of physical activity in patients with breast cancer may
aggregate reduced muscle mass and function that may
further impair their work capacity.
Anthracycline-mediated muscular toxicity is associated
with increased autophagy gene transcription in peripheral
muscle. The influx of super-anion production at complex 1
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damage to calcium-handling proteins that are responsible
for the activation of the autophagy genes [77]. Neverthe-
less, anthracycline-induced toxicity is also mediated by
accumulation of ROS leading to oxidative damage and
activation of pro-apoptotic genes and deregulated calpain
and caspase-3 systems within muscle fibres [78]. An inves-
tigation by Smuder et al [79] provides some evidence of
skeletal muscle apoptosis due to ROS accumulation within
the skeletal muscle, which may be mediated by similar
mechanisms previously described in the heart. Importantly,
endurance exercise before the administration of doxoru-
bicin attenuated autophagy gene amplification and skeletal
muscle apoptosis of the soleus muscle, suggesting that
endurance exercise is effective for protecting against loss
of skeletal muscle mass and function induced by chemo-
therapy treatment.
A series of cellular changes is also evident following
chemotherapeutic drug administration for the treatment of
breast cancer in peripheral muscle influencing contractile
impairment of slow-twitch and fast-twitch muscle fibres
[80]. Many authors have shown impaired regulation of
intracellular calcium reuptake and production from the
sarcoplasmic reticulum of skeletal muscle in animals treated
with anthracyclines due to mitochondrial ROS generation
[81,82]. Accumulation of intracellular calcium due to an in-
crease in calcium release and depressed reuptake are asso-
ciated with impaired force frequency, relaxation times, and
contractile impairment of fast-twitch and slow-twitch mus-
cle fibres [80]. Despite these findings, individuals with breast
cancer experience a loss of function and reduced peripheral
musclemass following chemotherapy treatment, leading toa
reduction in oxygen uptake and metabolism. Further inves-
tigation is needed to determine peripheral muscle adapta-
tions in human studies and their influence on exercise
tolerance for women with breast cancer.Oxygen transport
Anaemia is a common side effect of breast cancer and its
treatments and is also associated with the chemothera-
peutic agents administered, their dosing schedule, and
duration of cytotoxic exposure [83]. Kirshner et al [84] re-
ported the incidence of moderate to severe anaemia in
patients with breast cancer undergoing adjuvant chemo-
therapy with doxorubicin and cyclophosphamide in up to
40% of patients. Anaemia is associated with a reduction in
haemoglobin concentrations leading to fatigue and reduced
exercise tolerance [85]. Further, significantly large pro-
portions of women have low haemoglobin concentrations
preceding treatment and are associated with poorer dis-
ease prognosis [83]. Low haemoglobin concentrations pre-
ceding cancer diagnosis may explain a proportion of the
attenuated exercise tolerance for these women, which is
augmented with the disease and related treatments.
Aerobic training has been shown to improve symptoms of
fatigue and increase exercise tolerance in women with
breast cancer [86,87]. Haemoglobin is a key determinant of
oxygen-carrying capacity, oxygen transport, VO2peak, and
exercise capacity [88]. The relative haemoglobin mass in
healthy individuals is a significant predictor of exercisetolerance; however, changes in haemoglobin mass do not
necessarily correlate with improvements in VO2peak [89].
Dolan et al 2010 [90] suggested that women with breast
cancer who receive chemotherapy and undergo an aerobic
training or resistance training intervention are able to
maintain their VO2peak during chemotherapy despite a sig-
nificant decline in haemoglobin levels with a moderate
relationship between haemoglobin and VO2peak. On
average, the participants had normal resting haemoglobin
concentration, and were able to maintain these levels
following treatment. Therefore, although a reduced hae-
moglobin concentration clearly can affect oxygen transport
and aerobic capacity, it is not clear whether a reduced
haemoglobin concentration plays a major role in the
reduced exercise capacity often observed during or after
chemotherapy.
Courneya et al [91] demonstrated favourable outcomes
for VO2peak in cancer patients with anaemia. This research
group combined darbepoetin alpha, a common drug used to
increase red blood cells in the treatment of anaemia, with
aerobic training and compared the outcome with a group
that received darbepoetin alpha alone. The darbepoetin
alpha plus aerobic training group showed greater improve-
ments in VO2peak and increased haemoglobin concentrations
at a lower dose of the drug compared with the darbepoetin
alpha alone group. The darbepoetin alpha group alone did
not improve their VO2peak following the intervention
despite an increase in haemoglobin levels. The potential for
a reduction in haemoglobin following cancer treatment is
clear; however, more investigation is required to fully
elucidate the effects of reduced haemoglobin on exercise
intolerance in breast cancer.
Conclusion
Direct myocardial and vascular insults may hinder VO2peak in
patients with breast cancer resulting from chemotherapy
treatment and the disease. Centrally, the inability to in-
crease SV and Q during exercise is secondary to changes in
both systolic and diastolic functions with considerable in-
dividual variations. Interventions to enhance LV mechanics/
function while increasing SV, Q, and VO2peak during exercise
are of importance for this population, and may attenuate a
myriad of co-morbid cardiotoxicities associated with
treatment. Breast cancer and its treatments may also result
in a sequence of peripheral maladaptations that may affect
VO2peak. In specific, peripheral muscle maladaptations lead
to reduced muscle mass and impaired muscle function as a
consequence of breast cancer treatments and/or lifestyle
perturbations. Finally, there is evidence to suggest that
chemotherapy treatment may reduce resting haemoglobin
levels for women with breast cancer, which may further
attenuate VO2peak for this patient population. Interventions
to improve or maintain VO2peak are needed for individuals
with breast cancer to improve the overall quality of life and
preserve functional independence during survivorship.
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